Olaparib after Initial Treatment Delays Ovarian Cancer Progression
Cancer Currents: An NCI Cancer Research Blog,
In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of…
In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of…
The FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer.
The FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical…
The FDA has granted Priority Review for the niraparib New Drug Application (NDA). Niraparib is a PARP inhibitor that is being…